Summary
Elevance Health, Inc. (ELV) has reaffirmed its full-year 2023 net income guidance for investors. The company expects net income to be greater than $29.50 per share, which includes approximately $3.20 per share attributable to net unfavorable items. Excluding these specific items, Elevance Health anticipates adjusted net income to exceed $32.70 per share. This guidance remains consistent with the financial outlook provided in the first quarter of 2023 and does not incorporate any additional adjustment items beyond those previously reported. This reaffirmation of guidance suggests management's confidence in the company's ongoing performance and its ability to navigate the current business environment. Investors should note that the guidance is subject to the inherent risks and uncertainties outlined in the company's forward-looking statements, including potential impacts from healthcare cost trends, regulatory changes, and competitive pressures. The company intends to communicate these projections and other forward-looking information during upcoming investor meetings.
Key Highlights
- 1Elevance Health reaffirms 2023 full-year net income guidance: greater than $29.50 per share.
- 2Company expects net unfavorable items of approximately $3.20 per share for the full year.
- 3Excluding unfavorable items, adjusted net income guidance is greater than $32.70 per share.
- 4Guidance is consistent with previously issued projections from the first quarter of 2023.
- 5No new adjustment items beyond Q1 2023 earnings release are included in current guidance.
- 6Information was disclosed in an Item 7.01 - Regulation FD Disclosure filing on June 13, 2023.